Zydus Cadila completes clinical trial for Saroglitazar Mg

Zydus Cadila has completed Phase 3 clinical trial in India of Saroglitazar Mg which is used for treating Type 2 Diabetes.

In India, Zydus Cadila launched Saroglitazar Magnesium in 2013, under the brand name of Lipaglyn to be used for the treatment of hypertriglyceridemia and diabetic dyslipidemia for patients suffering from Type-2 diabetes and not being controlled by statins. The specifications of the trial include it being multi-centric, randomised, double-blind study consisting of 1,140 subjects being studied for a period of 56 weeks for evaluating safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with Type 2 diabetes mellitus. Successful results of the clinical trial showed change from baseline in glycosylated haemoglobin (HbAlc) for Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg at 24 weeks. For patients with Type-2 diabetes, insulin resistance is a root cause and Saroglitazar Mg achieved its aim of being a next-generation insulin sensitiser without having the side effects of edema and weight gain which are usually known to emerge as a potent anti-diabetic agent for many patients.

Cadila Healthcare Limited is one of India’s leading pharmaceutical company headquartered in Ahmedabad, Gujarat. The company is engaged in developing, manufacturing and marketing products for healthcare therapies which also includes small molecule drugs, biologic therapeutics and vaccines and other generic drugs.

On Friday, the stock of the Cadila Healthcare opened at Rs. 222.20 per share and was trading at Rs. 224.50, a decrease by 0.77 per cent or Rs. 1.75 per share. The intra-day high is Rs. 230.20 and intra-day low is Rs. 220.25. The 52-week high is Rs. 432.40 and 52-week low is Rs. 216.30 on BSE.